Cogent Biosciences announces ‘positive’ Part 1b data from SUMMIT trial

Cogent Biosciences reported “positive” Part 1b data from the company’s ongoing SUMMIT trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis, or NonAdvSM, at the 2024 American Academy of Allergy Asthma & Immunology Annual Meeting, or AAAAI, meeting taking place February 23-26. “We are pleased to announce these positive results from our SUMMIT Part 1b trial, the specifics of our new MS2D2 symptomatic severity PRO measure, and the news that we have initiated SUMMIT Part 2, with extremely positive support from the NonAdvSM community,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “The magnitude and speed of symptomatic reductions, along with corresponding improvements in quality-of-life, reported by patients in SUMMIT Part 1b has not been seen previously with other treatment options in this patient population. We are fully dedicated to our three actively enrolling, registration-directed clinical trials and see a clear path to establishing bezuclastinib as the best-in-class KIT mutant inhibitor for patients fighting systemic mastocytosis and gastrointestinal stromal tumors.”